Important Update
Our law firm is no longer accepting new Oxbryta cases. For other legal inquiries, visit our contact page.
Oxbryta and Sickle Cell: When a Treatment Causes Vaso-Occlusive Crises
For the Sickle Cell Disease (SCD) community, Oxbryta (voxelotor) was marketed as a breakthrough. Approved by the FDA in 2019, it promised to treat the root cause of the disease—preventing red blood cells from sickling—rather than just managing pain.
However, in September 2024, Pfizer voluntarily withdrew Oxbryta from the global market.
Following Pfizer’s voluntary withdrawal, major regulatory authorities—including the FDA Safety Alert Division and the European Medicines Agency (EMA)—formally suspended market authorizations worldwide.
The Oxbryta Paradox
Clinical data revealed a devastating paradox: the drug designed to prevent complications was allegedly causing higher rates of Vaso-Occlusive Crises (VOCs) and even death compared to a placebo.
If you or your child took Oxbryta—including pediatric dispersible formulations—and experienced increased hospitalizations, the drug itself may have caused these complications rather than a natural disease progression.
Oxbryta Lawsuit Updates
July 2026 Update – Oxbryta Litigation Status
NGRV attorneys continue to investigate claims involving Oxbryta following Pfizer’s worldwide withdrawal of the sickle-cell medication. Because Oxbryta litigation remains in its early stages, there is not yet a consolidated federal Multidistrict Litigation (MDL) proceeding. However, individual case evaluations continue, and initial federal bellwether test trials are scheduled to begin in mid-2027. NGRV is actively investigating claims against Pfizer on behalf of patients who experienced worsened vaso-occlusive crises or other severe complications while taking the medication.
The “Paradox”: Why Is Oxbryta Being Sued?
The central allegation in these lawsuits is a “failure to warn” regarding dangerous side effects.
Oxbryta works by binding to hemoglobin to keep red blood cells oxygenated. However, clinical studies and FDA post-market monitoring logged over 20,000 adverse event reports and more than 300 death reports related to sickle cell crises in patients prescribed Oxbryta. Instead of protection, patients experienced:
- A higher frequency of severe pain crises (VOCs).
- Unexpected organ failure (liver, kidney, or lung damage).
- An increased risk of stroke.
Do You Qualify For An Oxbryta Lawsuit?
Nigh Goldenberg is actively reviewing claims for individuals prescribed Oxbryta who experienced severe adverse events. Qualifications include:
| Qualification Category | Eligibility Criteria |
|---|---|
| 1. Prescription History | Documented prescription of Oxbryta (voxelotor) for Sickle Cell Disease. |
| 2. Primary Injuries |
• Hospitalization for Vaso-Occlusive Crises (VOCs) • Ischemic or Hemorrhagic Stroke • Diagnosed Organ Damage (Liver, Kidney, or Lung) • Fatal Complications / Wrongful Death |
| 3. Timeline | Setbacks or worsened symptoms occurred after starting Oxbryta therapy. |
“I Thought It Was Just My Sickle Cell…”
Because VOCs and organ damage are inherent risks of Sickle Cell Disease, many patients assumed their symptoms were worsening naturally. However, clinical withdrawal data points to a direct causal link between the medication and these complications. Our legal team works alongside medical experts to evaluate pharmacy records and determine if your timeline supports a defective drug claim.
Frequently Asked Questions
No. A voluntary market removal does not clear a manufacturer of liability if they failed to properly warn patients and physicians of known risks while the drug was actively marketed.
You remain eligible. If you took Oxbryta previously and experienced severe VOCs, stroke, or organ failure during or shortly after treatment, you may pursue a claim.
No. These cases are handled as individual personal injury claims within mass tort litigation, ensuring your specific damages, medical expenses, and suffering are individually compensated.
Steps To Take Now
Important Update
Our law firm is no longer accepting new Oxbryta cases. For other legal inquiries, visit our contact page.
